BRPI0608074A2 - derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo - Google Patents
derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmoInfo
- Publication number
- BRPI0608074A2 BRPI0608074A2 BRPI0608074-0A BRPI0608074A BRPI0608074A2 BR PI0608074 A2 BRPI0608074 A2 BR PI0608074A2 BR PI0608074 A BRPI0608074 A BR PI0608074A BR PI0608074 A2 BRPI0608074 A2 BR PI0608074A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonistic activity
- diaza
- spiro
- combined
- substituted oxa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE OXA-DIAZA-ESPIRO-[5.5]-UNDECANONA SUBSTITUIDOS E USO COMO ANTAGONISTAS DA NEUROCININA DO MESMO. A presente invenção refere-se a derivados de oxa-diaza-espiro[5.5]-undecanona substituidos tendo atividade antagonista de neurocinina, em particular uma atividade antagonista de NK~ 1~, uma atividade antagonista de NK~ 3~, uma atividade antagonista de NK~ 1~/NK~ 2~ combinada e uma atividade antagonista de NK~ 1~/NK~ 2~/NK~ 3~ combinada, sua preparação, composições compreendendo os mesmos e seu uso como um medicamento, em particular para o tratamento e/ou profilaxia de esquizofrenia, êmese, ansiedade e depressão, síndrome do intestino irritável (IBS), distúrbios do ritmo circadiano, pré-eclãmpsia, nonicepçáo, dor, em particular dor visceral e neuropática, pancreatite, inflamação neurogênica, asma, doença pulmonar obstrutiva crónica (COPD) e distúrbios da micção tais como incontinência urinária. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (1) e compreendem os sais de adição de ácido ou base farmaceuticamente aceitáveis dos mesmos, as formas estereoquimicamente isoméricas dos mesmos, a forma N-óxido dos mesmos e pró-fármacos dos mesmos, em que todos os substituintes são definidos como na reivindicação 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05101657 | 2005-03-03 | ||
| PCT/EP2006/060419 WO2006094934A1 (en) | 2005-03-03 | 2006-03-03 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0608074A2 true BRPI0608074A2 (pt) | 2009-11-03 |
Family
ID=34938877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0608074-0A BRPI0608074A2 (pt) | 2005-03-03 | 2006-03-03 | derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8138334B2 (pt) |
| EP (1) | EP1874783B1 (pt) |
| JP (1) | JP5094422B2 (pt) |
| KR (1) | KR101355064B1 (pt) |
| CN (1) | CN101133064B (pt) |
| AT (1) | ATE469159T1 (pt) |
| AU (1) | AU2006222061B2 (pt) |
| BR (1) | BRPI0608074A2 (pt) |
| CA (1) | CA2598530C (pt) |
| DE (1) | DE602006014531D1 (pt) |
| EA (1) | EA012421B1 (pt) |
| ES (1) | ES2346147T3 (pt) |
| MX (1) | MX2007010728A (pt) |
| NZ (1) | NZ556629A (pt) |
| WO (1) | WO2006094934A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| US10314835B2 (en) | 2014-06-25 | 2019-06-11 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
| KR101579688B1 (ko) | 2014-07-08 | 2015-12-24 | 재단법인 전남생물산업진흥원 | 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물 |
| EP3704271A4 (en) | 2017-11-02 | 2021-09-08 | California Institute of Technology | NEUROKININ ANTAGONISTS AND RELATED USES |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| TW382017B (en) | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
| AU9540898A (en) | 1997-08-29 | 1999-03-22 | Dsm N.V. | Granules free of excipients |
| US6482829B2 (en) * | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| ATE450504T1 (de) | 2000-08-10 | 2009-12-15 | Mitsubishi Tanabe Pharma Corp | Prolinderivative und deren verwendung als medikamente |
| CA2447329C (en) * | 2001-05-14 | 2009-07-28 | F.Hoffmann-La Roche Ag | 1-oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor |
| NZ571695A (en) | 2001-12-28 | 2010-02-26 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| EP1635811A2 (en) * | 2003-06-10 | 2006-03-22 | Janssen Pharmaceutica N.V. | Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| KR100863854B1 (ko) * | 2004-02-10 | 2008-10-15 | 에프. 호프만-라 로슈 아게 | 케모카인 ｃｃｒ5 수용체 조절제 |
-
2006
- 2006-03-03 NZ NZ556629A patent/NZ556629A/en not_active IP Right Cessation
- 2006-03-03 ES ES06708618T patent/ES2346147T3/es active Active
- 2006-03-03 AU AU2006222061A patent/AU2006222061B2/en not_active Ceased
- 2006-03-03 DE DE602006014531T patent/DE602006014531D1/de active Active
- 2006-03-03 US US11/913,890 patent/US8138334B2/en not_active Expired - Fee Related
- 2006-03-03 EP EP06708618A patent/EP1874783B1/en active Active
- 2006-03-03 AT AT06708618T patent/ATE469159T1/de not_active IP Right Cessation
- 2006-03-03 KR KR1020077020930A patent/KR101355064B1/ko not_active IP Right Cessation
- 2006-03-03 WO PCT/EP2006/060419 patent/WO2006094934A1/en active Application Filing
- 2006-03-03 BR BRPI0608074-0A patent/BRPI0608074A2/pt not_active IP Right Cessation
- 2006-03-03 MX MX2007010728A patent/MX2007010728A/es active IP Right Grant
- 2006-03-03 JP JP2007557517A patent/JP5094422B2/ja not_active Expired - Fee Related
- 2006-03-03 CA CA2598530A patent/CA2598530C/en not_active Expired - Fee Related
- 2006-03-03 EA EA200701879A patent/EA012421B1/ru not_active IP Right Cessation
- 2006-03-03 CN CN2006800066125A patent/CN101133064B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100292228A1 (en) | 2010-11-18 |
| EA012421B1 (ru) | 2009-10-30 |
| ES2346147T3 (es) | 2010-10-11 |
| CN101133064A (zh) | 2008-02-27 |
| WO2006094934A8 (en) | 2006-12-07 |
| CN101133064B (zh) | 2011-02-23 |
| WO2006094934A1 (en) | 2006-09-14 |
| EP1874783A1 (en) | 2008-01-09 |
| ATE469159T1 (de) | 2010-06-15 |
| US8138334B2 (en) | 2012-03-20 |
| MX2007010728A (es) | 2007-10-12 |
| AU2006222061A1 (en) | 2006-09-14 |
| CA2598530A1 (en) | 2006-09-14 |
| JP2008531659A (ja) | 2008-08-14 |
| NZ556629A (en) | 2010-04-30 |
| DE602006014531D1 (de) | 2010-07-08 |
| EP1874783B1 (en) | 2010-05-26 |
| JP5094422B2 (ja) | 2012-12-12 |
| CA2598530C (en) | 2014-12-16 |
| AU2006222061B2 (en) | 2011-04-28 |
| KR20070113224A (ko) | 2007-11-28 |
| KR101355064B1 (ko) | 2014-01-24 |
| EA200701879A1 (ru) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200604198A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| JO2527B1 (en) | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines | |
| TW200603797A (en) | Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | |
| BRPI0608074A2 (pt) | derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo | |
| NO331174B1 (no) | Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| WO2008080844A9 (en) | Azaspiro derivatives | |
| SG154443A1 (en) | Piperidine derivatives as nk1 antagonists | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| WO2010018112A3 (en) | Monoaryl aminotetralines | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| EA200801342A1 (ru) | 3-(4-{[4-(4-{[3-(3,3-диметил-1-пиперидинил)пропил]окси}фенил)-1-пиперидинил]карбонил}-1-нафталинил)пропановая или пропеновая кислота в качестве антагонистов н1 и н3-рецепторов для лечения воспалительных и аллергических расстройств | |
| ATE478075T1 (de) | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten | |
| MX2009006454A (es) | Derivados de espiro-piperidina. | |
| MX2009005544A (es) | Indoles. | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| HRP20050554B1 (hr) | Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista | |
| MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
| MX2009006446A (es) | Derivados de espiro-piperidina. | |
| MY145168A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| CY1107890T1 (el) | Υποκατεστημενα παραγωγα 1-πιπεριδιν-3-υλ-4-πιπεριδιν-4-υλ-πιπεραζινης και χρηση τους ως ανταγωνιστων της νευροκινινης | |
| TH82341A (th) | อนุพันธ์ของไดอะซา-สปิโร-[4.5]-เดคเคนและการใช้ของมันเป็นแอนทาโกนิสท์ของนิวโรไคนิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |